Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9de32f6289dcf304fcf935f042feceae http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
filingDate |
2017-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89f5d0766d9cbd0b0e60ab9c5d265cd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbdbb53260ac688b311c33e814c89dbe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d08a56eeb5805ee34a47d084b4661e2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdd25a154f8b7ef76ad4509c4e23ec7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_710053dea91fa99e8a1a28f180eec385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e133c507183f25806e0e8811b77c90f8 |
publicationDate |
2017-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2017349651-A1 |
titleOfInvention |
Prevention and treatment of synucleinopathic and amyloidogenic disease |
abstract |
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful prophylactic and therapeutic treatment of Parkinson's disease. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11142570-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017204173-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11292831-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11261242-B2 |
priorityDate |
2007-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |